|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Total cost of revenue | |||||
| Gross income before impact of changes in fair value | |||||
| Unrealized changes to fair value adjustments of biological assets | |||||
| Loss from fair value changes realized in the current year | |||||
| Gross profit | |||||
| Research and development expenses | |||||
| General and administrative expenses | |||||
| Sales and marketing expenses | |||||
| Other expenses (income), net | |||||
| Changes in the fair value of financial assets through profit or loss, net | |||||
| Total expenses recognized from share-based payment transactions | |||||
| Share of profit of investees accounted for using the equity method | |||||
| Operating loss | |||||
| Financing income | |||||
| Financing expenses | |||||
| Financing expenses, net | |||||
| loss before taxes on income | |||||
| Tax (expense) benefit | |||||
| Total comprehensive loss for the year | |||||
| Attribution of net loss for the year: | |||||
| To the Company’s shareholders | |||||
| To non-controlling interests | |||||
| Total | |||||
| Loss per share | |||||
| Basic loss | |||||
| Diluted loss | |||||
Loading...
